- Home
- SGMT vs III Comparison
SGMT vs III Comparison
Compare SGMT & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- III
- Stock Information
- Founded
- SGMT 2006
- III 2006
- Country
- SGMT United States
- III United States
- Employees
- SGMT N/A
- III N/A
- Industry
- SGMT
- III Professional Services
- Sector
- SGMT
- III Consumer Discretionary
- Exchange
- SGMT Nasdaq
- III Nasdaq
- Market Cap
- SGMT 269.2M
- III 227.5M
- IPO Year
- SGMT 2023
- III 2007
- Fundamental
- Price
- SGMT $7.90
- III $5.11
- Analyst Decision
- SGMT Strong Buy
- III Buy
- Analyst Count
- SGMT 5
- III 1
- Target Price
- SGMT $26.60
- III $5.50
- AVG Volume (30 Days)
- SGMT 3.5M
- III 204.4K
- Earning Date
- SGMT 08-13-2025
- III 08-04-2025
- Dividend Yield
- SGMT N/A
- III 3.63%
- EPS Growth
- SGMT N/A
- III N/A
- EPS
- SGMT N/A
- III 0.16
- Revenue
- SGMT N/A
- III $242,899,000.00
- Revenue This Year
- SGMT N/A
- III N/A
- Revenue Next Year
- SGMT N/A
- III $5.08
- P/E Ratio
- SGMT N/A
- III $31.68
- Revenue Growth
- SGMT N/A
- III N/A
- 52 Week Low
- SGMT $1.73
- III $2.95
- 52 Week High
- SGMT $10.43
- III $5.05
- Technical
- Relative Strength Index (RSI)
- SGMT 58.38
- III 67.11
- Support Level
- SGMT $7.51
- III $4.51
- Resistance Level
- SGMT $8.61
- III $4.79
- Average True Range (ATR)
- SGMT 1.14
- III 0.14
- MACD
- SGMT -0.14
- III 0.02
- Stochastic Oscillator
- SGMT 34.67
- III 98.43
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.